First BAFF/APRIL Dual Inhibitor Validates B-Cell Survival Pathway

Summary The U.S. FDA granted accelerated approval to TRUTAKNA™ (atacicept-vymj) for adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. Developed by Vera Therapeutics, TRUTAKNA is the first therapy to simultaneously inhibit both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing…